ReviewFrontiers in pharmacology2025
Targeting the cGAS-STING pathway: emerging strategies and challenges for the treatment of inflammatory skin diseases.
Review in Frontiers in pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed.
- The cGAS-STING pathway: mechanistic basis, dual biological functions and translational therapeutic advances.Apoptosis : an international journal on programmed cell death · 2026Review
- Photocontrolled immunotherapy: a BODIPY-caged MSA-2 for spatiotemporal activation of STING with visible light.New journal of chemistry = Nouveau journal de chimie · 2026Article
- Spotlight on cGAS-STING: role in disease pathogenesis and therapeutic potential.Molecular biomedicine · 2026Review
- Oxidative stress-mediated DNA fragmentation involved in STING-dependent apoptosis in human keratinocytes by 5-amino-2-methylphenol under ambient UVB exposure.Archives of toxicology · 2026Article
- Study on the Function and Mechanism of Neutrophil Extracellular Traps in Regulating Necroptosis Following Traumatic Brain Injury.Brain and behavior · 2026Article
- cGAS-STING Pathway in Gastrointestinal Malignancies: Mechanistic Insights and Translational Therapeutic Opportunities.Journal of gastrointestinal cancer · 2026Review
- Crosstalk between innate immune signaling pathways and integrated TLR, NLRP3 inflammasome, cGAS-STING, and NF-κB networks in sepsis.Frontiers in cell and developmental biology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The cGAS-STING signaling pathway is a major component of innate immunity. It is critical for identifying cytoplasmic DNA, triggering immune responses, and is linked to several diseases and malignancies. The inflammatory infiltrates and elevated cytokine expression characteristic of dermatological inflammatory disorders have drawn attention to the potential role of the cGAS-STING pathway, positioning it as an emerging focus of scientific investigation. Therapeutic strategies targeting the cGAS-STING signaling axis have been explored for the treatment of inflammatory dermatoses, with several inhibitor classes under investigation, such as cGAS inhibitors, STING palmitoylation blockers, STING trafficking suppressors, and nanoformulated inhibitors. Nevertheless, there are problems in both this pathway and drug research still left to be solved: inhibitors are not generally specific enough, drugs are not generally bioavailable enough, and there is an imbalance between the two-immunosuppression and the immune response. The several possible approaches in the future directions include combination therapy, multi-omics integration, and precision medicine approaches to treat these diseases. Given its broad immunomodulatory effects, there is high potential for clinical application of the cGAS-STING pathway modulators.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.